ArticleProceedings of the National Academy of Sciences of the United States of America2015

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.

Maria Giuseppina Baratta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.